Michael Haichin

@michaelhaichin.bsky.social

Basketball & drugs enthusiast. Pronounced "hi-kin" Medical Advisor for @psychedelicalpha.bsky.social

Got interviewed by the Microdose newsletter on the intersection of #psychedelic and #placebo research and on why psychedelic research should revisit the long forgotten Zelen design to solve the "know-cebo" problem. Enjoy! themicrodose.substack.com/p/the-power-...

The power of “know-cebo”: 5 Questions for data scientist Balázs Szigeti

Szigeti discusses expectancy effects, unblinding, and how researchers might design better studies on psychedelics.

themicrodose.substack.com

Our new review in JAMA Psychiatry: "Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders" jamanetwork.com/journals/jam... Thanks to co-first author Guil Fusetto-Veronesi; and to Samuele Cortese, David Baldwin, Matt Garner 🧵👇

Expectancy Effects, Blinding Integrity, and Placebo Response in Psychiatric Disorders

This narrative review discusses the impact of expectancy effects and functional unblinding on treatment responses in randomized clinical trials of treatments in psychiatry.

jamanetwork.com

New: The Q1'25 Edition of our Psychedelic Drug Development Pipeline Bullseye Chart is now available to download. Get an overview of psychedelic candidates by molecule type and phase of development via this handy visual. psychedelicalpha.com/news/q125-ps...

Q1’25 Psychedelic Drug Development Pipeline: Bullseye Chart - Psychedelic Alpha

We present the psychedelic drug development pipeline in a ‘bullseye chart’ format, as of Q1’25.

psychedelicalpha.com

Psychedelic mental health research is booming—but how do we keep up with rapidly evolving evidence? 🌱 Our team proposes a living evidence synthesis approach to ensure clinicians, policymakers, and the public have access to the latest, most reliable data. 🔗 www.nature.com/articles/s44... 🧪🧵

An initiative for living evidence synthesis in clinical psychedelic research - Nature Mental Health

Renewed interest in psychedelics as treatments for mental disorders has recently emerged, but substantial challenges remain in obtaining evidence from available data to inform clinical decision-making...

nature.com

"Navigating this new world will require a more precise understanding of the psychoactive substances that are now part of it. Instead of attempting to sort chemical compounds into good and bad, we could pay more attention to how people use them." - @mikejay.bsky.social www.nytimes.com/2024/12/23/o...

Opinion | As Drug Culture Becomes Mainstream, Our Language Needs To Evolve. (Gift Article)

We need a new language to talk about the chemicals and plants that change our consciousness.

nytimes.com

New paper! This was a fun lil collaboration with Maastricht University in which we thought we might find evidence that ayahuasca would increase false memory in an observational study. WRONG! Ended up enhancing memory (but read 'til end for caveats) journals.sagepub.com/doi/10.1177/... 1/8

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

Psychoactive-controlled ketamine for OCD study doi.org/10.1177/0269... "We did not assess blinding...prominent differences in dissociation scores...suggest that fentanyl 50 μg also did not provide an adequate blind...would not recommend its use (but do not have a suitable alternative to recommend)."

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

doi.org

Psychoactive-controlled ketamine for OCD study doi.org/10.1177/0269... "We did not assess blinding...prominent differences in dissociation scores...suggest that fentanyl 50 μg also did not provide an adequate blind...would not recommend its use (but do not have a suitable alternative to recommend)."

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

doi.org